ASLAN Pharmaceuticals Future Growth
Future criteria checks 0/6
ASLAN Pharmaceuticals's revenue and earnings are forecast to decline at 171.4% and 14.9% per annum respectively while EPS is expected to grow by 4.6% per annum.
Key information
-14.9%
Earnings growth rate
4.6%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | -171.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -56 | N/A | N/A | 1 |
12/31/2024 | N/A | -66 | N/A | N/A | 2 |
12/31/2023 | 12 | -44 | -47 | -47 | N/A |
9/30/2023 | 12 | -45 | N/A | N/A | N/A |
6/30/2023 | 12 | -46 | -59 | -59 | N/A |
3/31/2023 | N/A | -58 | N/A | N/A | N/A |
12/31/2022 | N/A | -51 | -38 | -38 | N/A |
9/30/2022 | N/A | -46 | N/A | N/A | N/A |
6/30/2022 | N/A | -45 | -36 | -36 | N/A |
3/31/2022 | N/A | -38 | N/A | N/A | N/A |
12/31/2021 | N/A | -31 | -34 | -34 | N/A |
9/30/2021 | N/A | -28 | N/A | N/A | N/A |
6/30/2021 | N/A | -21 | -21 | -21 | N/A |
3/31/2021 | N/A | -20 | N/A | N/A | N/A |
12/31/2020 | N/A | -16 | -15 | -15 | N/A |
9/30/2020 | N/A | -40 | -15 | -15 | N/A |
6/30/2020 | 0 | -41 | -20 | -20 | N/A |
3/31/2020 | N/A | -47 | -24 | -24 | N/A |
12/31/2019 | 3 | -47 | -26 | -26 | N/A |
9/30/2019 | 3 | -27 | -29 | -29 | N/A |
6/30/2019 | 3 | -34 | -34 | -33 | N/A |
3/31/2019 | 3 | -37 | -47 | -36 | N/A |
12/31/2018 | N/A | -42 | -63 | -39 | N/A |
9/30/2018 | N/A | -45 | -63 | -40 | N/A |
6/30/2018 | N/A | -41 | -61 | -38 | N/A |
3/31/2018 | N/A | -42 | -52 | -40 | N/A |
12/31/2017 | N/A | -41 | -35 | -35 | N/A |
9/30/2017 | 1 | -33 | N/A | -30 | N/A |
6/30/2017 | 12 | -19 | N/A | -14 | N/A |
3/31/2017 | 12 | -14 | N/A | -8 | N/A |
12/31/2016 | 11 | -9 | N/A | -6 | N/A |
9/30/2016 | 11 | -7 | N/A | -7 | N/A |
6/30/2016 | 0 | -15 | N/A | -13 | N/A |
3/31/2016 | N/A | -15 | N/A | -13 | N/A |
12/31/2015 | N/A | -14 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ASLN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ASLN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ASLN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ASLN is forecast to have no revenue next year.
High Growth Revenue: ASLN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ASLN's Return on Equity is forecast to be high in 3 years time